FDA approves 2mg dose of Ozempic (semaglutide) for T2DM
0.25mg weekly x 4 weeks (to avoid GI side effects)
0.5mg weekly as maintenance dose, if tolerating after 4 weeks and need additional glucose control, may increase to 1mg weekly. After 4 weeks if tolerating, may increase to 2mg weekly.
2mg/1.5mL pen: 0.25mg or 0.5mg doses
4mg/3mL pen: 1mg doses
8mg/3mL pen: 2mg doses
Trial Data – SUSTAIN FORTE:Efficacy and Safety of once weekly semaglutide 2mg vs 1mg in patients with T2DM; double blind, randomized trial
In the SUSTAIN FORTE trial, people with an average starting A1C of 8.9% treated with Ozempic® 2 mg achieved a statistically significant and superior reduction in blood sugar of 2.1% at week 40 compared to 1.9% with Ozempic® 1 mg (P<0.01). Average starting weight of 219 lb treated with Ozempic® 2 mg experienced a weight loss of 14.1 lb compared to a weight loss of 12.5 lb with Ozempic® 1 mg; the difference was not statistically significant. For both doses of Ozempic®, there were no new safety signals identified. The most common adverse events were gastrointestinal. Gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic® 2 mg (34.0%) vs Ozempic® 1 mg (30.8%).
Does anyone already have patients in mind that they plan to titrate?